RC48 Clinical Trials
4 recruitingDrug
Phase 24Phase 11
Showing 1–4 of 4 trials
Recruiting
Phase 2
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
GC/GEJC
The First Affiliated Hospital with Nanjing Medical University124 enrolled1 locationNCT07474324
Recruiting
Phase 2
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
Mammary or Extramammary Paget's Disease
Fudan University36 enrolled1 locationNCT06561555
Recruiting
Phase 1Phase 2
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Prostate CancerCDK12 Gene Mutation
Tianjin Medical University Second Hospital72 enrolled1 locationNCT06663007
Recruiting
Phase 2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital20 enrolled1 locationNCT05957757